| DOI: 10.29090/psa.2020.03.019.0076 | Pharm Sci Asia ; 47(3), 221-225 |
The role of corticosteroid for the treatment of Coronavirus Disease-2019 (COVID-19): A narrative reviewOki Nugraha Putra*, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
- Department of Clinical Pharmacy, Program Study of Pharmacy, Hang Tuah University, Arief Rahman Hakim 150, Surabaya, East Java – Indonesia
Acute respiratory distress syndrome (ARDS) is a most common complication in patients with severe COVID-19 with high rate of mortality. Corticosteroids have been used in the management of SARS-CoV and MERS-CoV several years ago. Data about the effectiveness of corticosteroids in the management of COVID-19 is lacking. It has been proposed that the corticosteroids have a modulatory effect by suppressing cytokine storms in severe COVID-19. The aimed of this study is to review literature that discussed the use of corticosteroids in patients with COVID-19 related ARDS. Pubmed database was used to select the article in this review with the keywords SARS-CoV-2, COVID-19, corticosteroid, pneumonia, and ARDS. Elderly and patients with underlying disease are more likely to develop severe COVID-19 and lead to ARDS. Because of the immunosuppressive activity, corticosteroid could modulate the cytokine storms in COVID-19 patients with ARDS. The use of corticosteroids may offer the benefit in COVID-19 with ARDS, by reduce the mortality rate and duration of treatment. The administration of corticosteroids should be considered in COVID-19 patients with signs of ARDS and refractory shock. The low until moderate dose and short treatment of corticosteroids are recommended to minimize the adverse effects.
Keyword:
COVID-19, ARDS, Corticosteroids, Cytokine Storms
Download full paper (PDF File size: 948.50 KB.)
|
